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ABSTRACT 69 
Introduction: This registry evaluated the 24-month safety and efficacy of levodopa-70 
carbidopa intestinal gel (LCIG) treatment in advanced Parkinson’s disease (PD) patients 71 
under routine clinical care. 72 
 73 
Methods: Motor fluctuations, dyskinesia, non-motor symptoms, quality of life, and 74 
safety were evaluated. Observations were fully prospective for treatment-naïve patients 75 
(60% of patients) and partially retrospective for patients with ≤ 12 months of pre-76 
treatment with LCIG (40% of patients). Hours of “On” and “Off” time were assessed with 77 
a modified version of the Unified Parkinson’s Disease Rating Scale part IV items 32 and 78 
39. 79 
 80 
Results: Overall, 375 patients were enrolled by 75 movement disorder centers in 18 81 
countries and 258 patients completed the registry. At 24 months LCIG treatment led to 82 
significant reductions from baseline in “Off” time (hours/day) (mean±SD = -4.1±3.5, 83 
P<0.001), “On” time with dyskinesia (hours/day) (-1.1±4.8, P=0.006), Non-Motor 84 
Symptom Scale total (-16.7±43.2, P<0.001) and individual domains scores, and 85 
Parkinson’s Disease Questionnaire-8 item total score (-7.1±21.0, P<0.001). Adverse 86 
events deemed to have a possible/probable causal relationship to treatment drug/device 87 
were reported in 194 (54%) patients; the most frequently reported were decreased 88 
weight (6.7%), device related infections (5.9%), device dislocations (4.8%), device 89 
issues (4.8%), and polyneuropathy (4.5%).  90 
 91 
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Conclusions: LCIG treatment led to sustained improvements in motor fluctuations, 92 
non-motor symptoms particularly sleep/fatigue, mood/cognition and gastrointestinal 93 
domains, as well as quality of life in advanced PD patients over 24 months. Safety 94 
events were consistent with the established safety profile of LCIG. 95 
 96 
INTRODUCTION 97 
Levodopa is the most efficacious drug for the treatment of Parkinson’s disease 98 
(PD), but the long-term use of standard oral administration is associated with the 99 
development of disabling motor complications in most patients. Fluctuations in motor 100 
response are related to fluctuating peripheral levodopa plasma levels and are often 101 
associated with a variety of non-motor symptoms [1-4].  These motor and non-motor 102 
complications are aggravated by erratic gastric emptying, and substantially impact daily 103 
activities, social interactions, and patient quality of life (QoL) [5, 6].  104 
Levodopa-carbidopa intestinal gel (LCIG, also carbidopa-levodopa enteral 105 
suspension in the United States, CLES) is continuously delivered to the upper intestine 106 
ensuring more stable levodopa plasma levels than standard oral levodopa therapy [7, 107 
8]. This reduces motor response fluctuations and has also been shown to improve non-108 
motor complaints commonly associated with chronic oral levodopa treatment [9-14].  109 
To date only a few studies have assessed the long-term safety and efficacy of 110 
LCIG treatment in routine clinical care and a majority of these studies included a limited 111 
number of patients or lacked systematic collection of efficacy data and adverse events 112 
[11, 15-19]. The objective of the GLORIA registry (global long-term registry on efficacy 113 
and safety of LCIG in patients with advanced Parkinson's disease in routine care) was 114 
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to prospectively evaluate the long-term effectiveness of LCIG on motor and non-motor 115 
symptoms (NMS), QoL, and safety in a large cohort of advanced PD patients. 116 
 117 
METHODS 118 
Study design 119 
In this 24-month (M), multi-national, non-interventional, observational registry, 120 
advanced PD patients with persistent motor complications received LCIG treatment at 121 
75 movement disorder centers across 18 countries (Australia, Austria, Belgium, 122 
Bulgaria, Czech Republic, Denmark, France, Germany, Greece, Ireland, Italy, 123 
Netherlands, Norway, Romania, Slovenia, Spain, Switzerland, and United Kingdom). 124 
The study protocol was approved by national and/or local independent ethics 125 
committees and health authorities at each participating institution and country. All 126 
patients provided written informed consent before enrollment in the registry. 127 
LCIG treatment was initiated via a temporary nasojejunal (NJ) tube to verify drug 128 
efficacy and optimize dose before being administered through PEG-J (according to local 129 
label and reimbursement criteria). Concomitant medications were permitted at the 130 
discretion of the treating physician. 131 
 132 
Patients 133 
Enrolled participants were male and female advanced PD patients with persistent 134 
severe motor complications that were eligible for LCIG treatment according to European 135 
Commission Summary Product Characteristics and national reimbursement criteria. 136 
Clinical observations were recorded prospectively for up to 24M for LCIG-naïve 137 
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patients. For patients who had received LCIG for ≤ 12M before enrollment in the 138 
registry, clinical observations were collected retrospectively up to the day of registry 139 
enrollment followed by prospective documentation for a total observation period of 24M. 140 
Efficacy and safety outcomes were comparable between the retrospective and 141 
prospective cohorts (Supplemental Table 1). 142 
 143 
Efficacy 144 
Efficacy outcomes included the mean change from baseline to study visit in the 145 
Unified Parkinson’s Disease Rating Scale (UPDRS) parts II, III, and IV; “Off” time and 146 
the dyskinesia items from UPDRS part IV. UPDRS IV items 39 and 32 were modified by 147 
using the rating instructions for the corresponding parts 4.3 and 4.1 of the MDS-UPDRS 148 
to allow for calculation of actual hours of “Off” time and “On” time with dyskinesias. 149 
UPDRS was conducted in the “On” state. NMS were assessed using the NMS Scale 150 
(NMSS) and patient reported QoL measures included the disease-specific 8-item 151 
Parkinson’s Disease Questionnaire (PDQ-8) and the generic EuroQoL- 5 Dimensions 152 
(EQ-5D) descriptive score and visual analog scale (VAS). Efficacy assessments were 153 
collected at baseline before LCIG treatment initiation with temporary NJ (concomitant 154 
PD medications were administered at the discretion of threating physician), at discharge 155 
from hospital following PEG-J placement (D1), 6M, 12M, 18M, and 24M. 156 
Primary efficacy analyses included all patients who had a baseline efficacy 157 
evaluation, received ≥ 1 dose of LCIG and ≥ 1 post-baseline safety and efficacy 158 
evaluation (N=329). Safety analyses included all patients who received ≥ 1 dose of 159 
LCIG and had ≥ 1 post-baseline safety evaluation (N=356). Last visit was defined as a 160 
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patient’s last reported study visit. ANOVA over time and paired t-tests were performed 161 
for the comparison of all efficacy outcomes to baseline. The targeted enrollment for 162 
adequate sample size was 400 patients. Missing data was accounted for using survey 163 
methodology. 164 
 165 
Safety 166 
Adverse drug reactions (ADRs), which included all adverse events with a 167 
reasonable possibility of being causally related to the treatment drug or device as 168 
determined by the investigator, were recorded for the duration of the registry and for 28 169 
days following a patient’s last reported study visit. ADRs were coded according to the 170 
Medical Dictionary for Regulatory Activities (MedDRA) [20] and categorized by the study 171 
investigator as mild, moderate or severe and as having an unlikely, possible or probable 172 
relationship to LCIG treatment. Serious ADRs and product complaints were monitored 173 
and recorded. Gastrointestinal (GI)-related ADRs reported by the investigator were 174 
categorized post hoc by the authors as either procedure-related, device-related, or 175 
“other” type of GI reaction not directly related to the procedure or device (e.g. decreased 176 
weight, nausea). Daily levodopa equivalent dose (LED) was calculated for the reported 177 
administration of LCIG and concomitant oral PD treatment for each study visit, 178 
according to published conversion factors [21]. 179 
 180 
RESULTS 181 
Of the 375 patients enrolled, 258 (69%) completed the registry (Supplemental 182 
Figure 1). The mean ± SD exposure to PEG-J was 640.7 ± 198.3 days. Patient 183 
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demographics, PD characteristics, and baseline assessments of motor symptoms, 184 
NMS, and QoL are summarized in Table 1. Over the course of the study, the 185 
percentage of patients receiving LCIG as a monotherapy ranged between 36-40% 186 
(36%, n=98/273 at M18; 40%, n=126/316 at M6) (Supplemental Table 2). The most 187 
common concomitant medications across all study visits were oral levodopa and 188 
dopamine agonists. Among patients that received LCIG as a monotherapy, the mean 189 
daily LED ranged from 1509 ± 719 mg at D1 (n=126) to a maximum of  1795 ± 878 mg 190 
at M18 (n=98). The mean daily LED for patients with LCIG combination therapy ranged 191 
from 1960 ± 873 mg at D1 (n=225) to a maximum of  2013 ± 880 mg at M6 (n=189) 192 
(Supplemental Table 2).  193 
 194 
Efficacy 195 
At last visit, LCIG-treated patients showed significant reductions in “Off” time 196 
compared to baseline (modified UPDRS IV item 39, mean change from baseline ± SD=-197 
3.9 ± 3.5 hours/day, 95% CI=[-4.4, -3.5], P<0.001, n=207) (Figure 1A). Significant and 198 
sustained reductions in “On” time with dyskinesia (modified UPDRS IV item 32) were 199 
also observed at last visit (-1.1 ± 4.7, 95% CI=[-1.8, -0.5], P<0.001, n=211) (Figure 1B). 200 
Additional improvements observed at last visit included UPDRS IV item 33 (dyskinesia 201 
severity, -0.9 ± 1.3, 95% CI=[-1.1, -0.7], P<0.001, n=188), UPDRS IV item 34 202 
(dyskinesia-related pain, -0.6 ± 1.2, 95% CI=[-0.8, -0.4], P<0.001, n=187), and UPDRS 203 
IV item 35 (early morning dystonia, -0.2 ± 0.6, 95% CI=[-0.2, -0.1], P<0.001, n=250). 204 
UPDRS II and III scores (assessed when “On”, Supplemental Table 3) showed 205 
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significant reductions compared to baseline through 18M (-2.0 ± 9.1, 95% CI=[-3.4, -206 
0.5], P=0.007) and 24M (-1.9 ± 11.8, 95% CI=[-3.6, -0.2], P=0.026), respectively.  207 
The NMSS total score was significantly reduced from baseline at all study visits 208 
with a mean change of -14.4 ± 44.8 at last visit (95% CI=[-20.3, -8.5], P<0.001, n=227) 209 
(Figure 2A). At last visit, 5/9 NMSS domain scores were significantly reduced compared 210 
to baseline: cardiovascular (last visit: mean change from baseline=-0.6 ± 4.1, 95% CI=[-211 
1.1, -0.0], P=0.044), sleep/fatigue (-4.5 ± 10.6, 95% CI=[-5.9, -3.1], P<0.001), 212 
mood/cognition (-2.8 ± 14.7, 95% CI = [-4.7, -0.9], P=0.004), gastrointestinal tract (-2.2 213 
± 7.3,  95% CI=[-3.1, -1.2], P<0.001), and miscellaneous (-1.5 ± 9.9, 95% CI=[-2.8, -214 
0.2], P=0.022) (Figure 2B and Supplemental Table 3). 215 
Quality of life, as measured by the PDQ-8, was significantly improved in LCIG-216 
treated patients at every study visit (last visit: -5.3 ± 20.7, 95% CI=[-8.2, -2.5], P<0.001, 217 
n=205) (Figure 2C). Significant improvements were maintained through last visit in three 218 
PDQ-8 items: item 1 (difficulty getting around in public places, -0.4 ± 1.4, 95% CI=[-0.6, 219 
-0.2], P<0.001), item 7 (had painful muscle cramps and pain, -0.3 ± 1.4, 95% CI=[-0.5, -220 
0.1], P=0.002), and item 8 (felt embarrassed by having PD, -0.5 ± 1.4, 95% CI=[-0.7, -221 
0.3], P<0.001) (Supplemental Table 4). Significant improvements were observed in the 222 
EQ-5D descriptive and VAS scores compared to baseline (18M: EQ-5D, 0.06 ± 0.34, 223 
95% CI=[0.0, 0.1], P=0.025; last visit: VAS, 11.9 ± 28.3, 95% CI=[7.9, 15.9], P<0.001) 224 
(Supplemental Table 4). 225 
 226 
Safety 227 
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Overall, 194 (54.5%, N=356) patients experienced one or more ADRs (Table 2). 228 
The most frequently reported ADRs during the PEG-J treatment period were decreased 229 
weight (6.7%, n=24), device-related infections (5.9%, n=21), device dislocations (4.8%, 230 
n=17), device issues (4.8%, n=17), and polyneuropathy (4.5%, n=16) (Table 2). Thirty-231 
nine percent of patients (n=139/356) reported ≥ 1 GI-related ADR during the PEG-J 232 
treatment period, of which procedure-related ADRs were reported in 35 patients (9.8%), 233 
device-related in 93 (26%), and other GI ADRs in 63 (18%). These AD s were 234 
generally transient, with the highest prevalence of GI-related ADRs (13.5%) and serious 235 
GI-related ADRs (4.5%) occurring during the first 2 weeks of LCIG treatment post-PEG-236 
J placement (Supplemental Figure 2). 237 
Serious ADRs occurred in 109 (30.6%) patients and 55 (15.4%) patients had a 238 
severe ADR (Table 2). Device dislocation was the most frequently reported serious 239 
ADR during the PEG-J treatment period (2.2%, n=8). Twenty-five (7.0%) patients 240 
experienced at least one ADR that led to discontinuation of LCIG treatment and device 241 
dislocation was the only ADR leading to discontinuation reported by more than 1 patient 242 
(n=2, 0.6%). 243 
Twenty-nine deaths (8%, N=356) occurred during the registry period: 23 were 244 
deemed unrelated to treatment, 5 possibly related, and 1 probably related (Table 2). Of 245 
the possibly related deaths, 2 were the result of pneumonia followed by septic shock 246 
and/or organ failure on treatment days 463 and 452, 1 occurred on treatment day 511 247 
and was the result of pneumonia followed by a stroke, 1 occurred on treatment day 425 248 
and was the result of a fatal seizure, and 1 occurred on treatment day 645 and was the 249 
result of unknown causes following a small bowel obstruction that occurred 3 weeks 250 
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before patient death. The patient death deemed probably related to treatment occurred 251 
after 646 days of treatment and was the result of a small bowel perforation and 252 
peritonitis.  253 
 254 
DISCUSSION 255 
This primary analysis of the GLORIA registry represents the largest cohort of 256 
advanced PD patients treated with LCIG and provides evidence for the long-term 257 
effectiveness in reducing motor fluctuations and dyskinesia during routine clinical care. 258 
In addition, there were improvements in QoL and a variety of non-motor symptoms, and 259 
the safety profile was overall satisfactory.  260 
LCIG led to sizable reductions in the amount of time patients spent in the “Off” 261 
state. On average, patients maintained at least a 50% reduction in “Off” time at every 262 
study visit. This reduction in “Off” time observed was well above the 1-hour change that 263 
is deemed clinically relevant [22] and was consistent with other published open-label 264 
studies and randomized controlled trials on LCIG [9-11]. 265 
“Off” time improvements occurred alongside reductions in the proportion of “On” 266 
time spent with dyskinesia. The average “On” time with dyskinesia was reduced by 25% 267 
at 24M. Importantly, this was observed despite increased total levodopa equivalent 268 
dose following the switch from oral levodopa to LCIG and increases in LED over the 269 
24M follow-up period. This is consistent with literature suggesting that switching to 270 
continuous levodopa delivery improves not only motor fluctuations but also reduces pre-271 
existing dyskinesia [2, 6, 9, 23, 24]. Increases in the daily levodopa dose are common in 272 
clinical practice when switching from oral PD medications to LCIG and similar 273 
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magnitudes of LED increase have been previously reported [17]. The continuous nature 274 
of levodopa delivery with LCIG often allows for an increase in LED for optimal motor 275 
symptom control while limiting many of the undesirable side effects associated with high 276 
oral levodopa dose. Given that GLORIA was a registry and not a controlled, clinical trial, 277 
there were no specific requirements for dose optimization prior to LCIG initiation. 278 
Procedures in this registry reflected the 'real-world' routine clinical setting, where 279 
treating physicians determined that all oral treatment options had been exhausted and 280 
LCIG was now indicated. 281 
Improvements in UPDRS II and III scores were also observed across the registry, 282 
however they were only significant through M18 (UPDRS II) while change at M24 in the 283 
UPDRS III score falls below the minimal clinically important difference threshold. These 284 
data are similar to those reported in previous studies examining LCIG treatment, 285 
including Palhagen et al. (2016) [27], and may reflect worsening/progression of the 286 
disease. It is important to note that QoL remained improved over all time points in a 287 
stable manner which is consistent with other studies on LCIG [9, 10, 27] 288 
Consistent with the interim analysis of this registry [12] and the EuroInf study 289 
[25], LCIG led to a significant reduction in NMS burden at 24M. NMS domains that 290 
showed persistent improvement over the entire follow-up period included the 291 
cardiovascular, sleep/fatigue, mood/cognition, gastrointestinal tract, and 292 
“miscellaneous” domains. Notably, disturbances in sleep/fatigue, which have a strong 293 
impact on QoL, showed the greatest magnitude of improvement at 24M, arguing for 294 
improved sleep quality as motor fluctuations improved [26].  295 
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Given the characteristics of this registry (which included some retrospective data) 296 
the safety analyses cannot be directly compared to previous studies, however the most 297 
frequently reported ADRs were consistent with the established safety profile of LCIG [9-298 
11, 28]. Device and procedure-related events were the most frequently reported ADRs 299 
and were generally transient, occurring at highest prevalence within the first 2 weeks 300 
post-PEG-J placement. These data emphasize the need for close monitoring in the 301 
immediate post-PEG-J placement period. Additionally, the GI-related ADRs were 302 
consistent with the known long-term complications of the PEG-J procedure [29]. Given 303 
the demographics of the registry population, LCIG procedure and treatment was 304 
generally well tolerated, with a low rate of discontinuation due to ADR (7.0%) that was 305 
consistent with previously published reports [10]. Of the 29 deaths that occurred during 306 
the registry, 5 were deemed possibly related to treatment and 1 was probably related to 307 
treatment. The determination of possibly related deaths was based upon the 308 
investigator’s judgment that there was reasonable support for an association between 309 
the treatment and an event (e.g. pneumonia); however, a causal relationship between 310 
treatment and death was undetermined. The 1 probably related death, resulting from of 311 
a fatal small bowel perforation, occurred after 646 days of treatment and underscores 312 
the invasiveness and inherent risks of chronic PEG-J use in an elderly population. 313 
Timely investigations of a patient’s abdominal complaints and the involvement of GI 314 
specialists and interdisciplinary care and management teams may reduce the inherent 315 
risks of chronic PEG-J use in the elderly. 316 
This registry provides important clinical data related to the use of LCIG to treat 317 
advanced PD patients, however there are some limitations associated with the registry 318 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Antonini, Poewe, et al. 
14 
 
design. These limitations include the registry’s open-label design and the lack of a 319 
control group, which does not allow for comparative efficacy and safety assessments. 320 
This limitation is particularly relevant in evaluating the significance of LCIG on NMS as a 321 
recent double-blind randomized study examining the effects of rotigotine and placebo 322 
on NMS severity in PD patients with severe non-motor disability demonstrated similar 323 
improvements (>30%) in both the treatment and placebo study groups [30]. Additional 324 
limitations include the statistical method employed for the efficacy analyses, which did 325 
not carry the last observation forward, and the partially retrospective nature of data 326 
collection for 40% of the enrolled patients, which resulted in some missing data during 327 
the documentation period. 328 
In conclusion, LCIG treatment in advanced PD patients in routine care led to 329 
significant and sustained reductions in motor fluctuations and NMS burden and 330 
improvements in QoL, despite natural PD progression over the 2-year follow-up. The 331 
safety results were consistent with the previously established safety profile of LCIG.  332 
 333 
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Figure Legends 628 
 629 
Figure 1. Motor symptom efficacy. Mean change from baseline of daily hours of A. 630 
"Off" time (modified UPDRS Part IV Items 39) and B. "On" time with dyskinesia 631 
(modified UPDRS Part IV Item 32). Error bars indicate SD. Asterisks indicate statistical 632 
significance compared to baseline in a paired t test at the P<0.01 (**) and P<0.001 (***) 633 
levels. UPDRS = Unified Parkinson's Disease Rating Scale; BL = baseline; D1 = 634 
discharge from hospital post-PEG-J placement; M = month; LV = patient’s last reported 635 
study visit. 636 
 637 
Figure 2. Non-motor symptom efficacy. Mean change from baseline in A. NMSS total 638 
score, B. NMSS domain scores over 2-year follow-up, and C. PDQ-8 total score. Error 639 
bars indicate SD. NMSS = Non-Motor Symptom Scale, PDQ-8 = Parkinson’s Disease 640 
Questionnaire 8-item, BL = baseline; D1 = discharge from hospital post-PEG-J 641 
placement; M = month; LV = patient’s last reported study visit. P<0.05 (*), P<0.01 (**), 642 
and P<0.001 (***) 643 
 644 
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Table 1. Baseline demographics and disease characteristics 
 
Characteristic Value 
Age, years, mean ± SD 66.4 ± 8.8 
Sex, n (%)  
Male 220 (58.7) 
Female 155 (41.3) 
LCIG History, n (%) 
 
LCIG-naïve 225 (60) 
LCIG ≤ 12M before enrollment 150 (40) 
Baseline LED, mg/day, mean ± SD 1319 ± 617 
PD duration, years, mean ± SD 12.7 ± 6.3 
Hoehn & Yahr, mean ± SD  
During “On” 2.8 ± 0.8 
During “Off” 4.0 ± 0.9 
UPDRS Part IV, hours/day, mean ± SD  
Modified item 39: “Off” time 6.0 ± 3.2 
Modified item 32: Time with dyskinesia 4.3 ± 3.8 
UPDRS Part II (activities of daily living), mean ± SD 16.5 ± 9.8 
UPDRS Part III (motor examination), mean ± SD 24.6 ± 12.0 
NMSS, total score, mean ± SD 69.2 ± 42.1 
PDQ-8 Total Score (quality of life), mean ± SD 46.8 ± 18.6 
EQ-5D score, mean ± SD 0.4 ± 0.32 
EQ-VAS score, mean ± SD 48.0 ± 21.3 
PD medications reported at baseline, n (%)  
Levodopa 367 (97.9) 
Dopamine agonists 253 (67.5) 
COMT inhibitors 212 (56.5) 
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MAO-B inhibitors 133 (35.5) 
Amantadine 102 (27.2) 
Other oral 50 (13.3) 
LCIG = levodopa-carbidopa intestinal gel, LED = levodopa equivalent dose, PD = Parkinson’s 
disease, UPDRS = Unified Parkinson’s Disease Rating Scale, NMSS = Non-motor symptom 
scale,PDQ-8 = Parkinson’s Disease Questionnaire 8-item, EQ-5D = Euro Quality of Life 5 
Dimensions, EQ-VAS = Euro Quality of Life Visual Analog Scale, COMT = catechol-O-
methyltransferase, MAO-B = monoamine oxidase 
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Table 2. Safety Summarya 
 
Safety n (% of N=356) 
Patients with at least one ADR 194 (55) 
Patients with at least one GI-related ADR  139 (39) 
Patients with at least one serious ADR 109 (31) 
Patients with at least one severe ADR 55 (15) 
Deaths 29 (8.1) 
Unrelated to treatment 23 (6.5) 
Possibly related to treatment 5 (1.4) 
Probably related to treatment 1 (0.3) 
ADRs occurring in ≥ 3% of patients  
Weight decreased 24 (6.7) 
Device related infection 21 (5.9) 
Device dislocation 17 (4.8) 
Device issue 17 (4.8) 
Polyneuropathy 16 (4.5) 
Device lead issue 14 (3.9) 
Medical device complication 13 (3.7) 
Abdominal pain 13 (3.7) 
Hallucination 12 (3.4) 
Serious ADRs occurring in ≥ 1% of patientsb  
Device dislocation 8 (2.2) 
Device issue 7 (2.0) 
Parkinson’s disease 7 (2.0) 
Parkinsonism 7 (2.0) 
Medical device complication 6 (1.7) 
Device malfunction 5 (1.4) 
Device occlusion 5 (1.4) 
Abdominal pain 4 (1.1) 
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Hallucination 4 (1.1) 
Pneumonia 4 (1.1) 
Polyneuropathy 4 (1.1) 
Gastrointestinal and gastrointestinal procedure-related ADRs are italicized. 
aData indicates incidence of ADRs 
bDuring 24 months of LCIG infusion via PEG-J 
ADR = adverse drug reaction (adverse events with a possible/probable relationship to the 
treatment drug or device), GI = gastrointestinal, LCIG = levodopa-carbidopa intestinal gel, PEG-
J = percutaneous endoscopic gastrojejunostomy 
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Highlights:  
 
• Long-term registry of LCIG treatment in patients with advanced Parkinson’s disease 
• LCIG was delivered over 24 months in a routine clinical care setting 
• LCIG treatment reduced “Off” time and dyskinesia time over 2 years  
• LCIG treatment improved non-motor symptoms and quality of life over 2 years 
• Adverse drug reactions were consistent with the established safety profile of LCIG 
